Segment Information

12 Months Ended

Dec. 31, 2019

Segment Reporting [Abstract]

Segment Information

Segment Information

We operate in a single segment, focusing on serving patients affected by rare diseases through the discovery, development and commercialization of life-changing therapies. Consistent with our operational structure, our chief operating decision maker manages and allocates resources at a global, consolidated level. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with our management reporting. Disclosures about net product sales and long-lived assets by geographic area are presented below.

Net Product Sales

Net product sales by product and geographic region are as follows:

	Year Ended December 31,						% Change
	2019		2018		2017		2019 compared to 2018		2018 compared to 2017
SOLIRIS
United States	$	2,014.0	$	1,588.4	$	1,235.0	26.8	%	28.6	%
Europe	1,049.8		1,036.7		985.2		1.3	%	5.2	%
Asia Pacific	423.5		382.0		328.1		10.9	%	16.4	%
Rest of World	459.1		555.9		595.8		(17.4	)%	(6.7	)%
	$	3,946.4	$	3,563.0	$	3,144.1	10.8	%	13.3	%
ULTOMIRIS
United States	$	236.8	$	—	$	—	**		**
Europe	52.2		—		—		**		**
Asia Pacific	49.9		—		—		**		**
Rest of World	—		—		—		**		**
	$	338.9	$	—	$	—	**		**
STRENSIQ
United States	$	451.7	$	374.3	$	280.1	20.7	%	33.6	%
Europe	77.0		61.7		35.6		24.8	%	73.3	%
Asia Pacific	50.4		27.9		18.6		80.6	%	50.0	%
Rest of World	13.4		11.2		5.5		19.6	%	**
	$	592.5	$	475.1	$	339.8	24.7	%	39.8	%
KANUMA
United States	$	60.0	$	51.3	$	42.4	17.0	%	21.0	%
Europe	27.1		21.6		14.6		25.5	%	47.9	%
Asia Pacific	4.6		3.7		2.7		24.3	%	37.0	%
Rest of World	20.5		15.4		5.9		33.1	%	**
	$	112.2	$	92.0	$	65.6	22.0	%	40.2	%
Total Net Product Sales	4,990.0		$	4,130.1	$	3,549.5	20.8	%	16.4	%

** Percentages not meaningful

Long-Lived Assets

Long-lived assets consist of property, plant and equipment.

	December 31,
	2019		2018
United States	$	272.8	$	468.3
Europe	889.6		1,001.1
Other	0.9		2.1
	$	1,163.3	$	1,471.5